Important Information for Regeneron Pharmaceuticals, Inc. Investors:
The Schall Law Firm, a renowned national shareholder rights litigation firm, is reminding investors of a significant class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN). The lawsuit alleges that Regeneron violated the Securities Exchange Act of 1934 Sections 10(b) and 20(a) and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission (SEC).
Class Period and Eligibility:
The Class Period is defined as the period from November 2, 2023, to October 30, 2024, inclusive. Investors who purchased Regeneron’s securities during this timeframe may be eligible to participate in the class action.
Allegations:
The complaint alleges that Regeneron made false and misleading statements and failed to disclose material information during the Class Period. Specifically, the Company is accused of downplaying the risks associated with its EYLEA® (aflibercept) injection, a treatment for various eye diseases. Regeneron reportedly withheld information regarding the potential for serious side effects, including retinal detachment and endophthalmitis. These issues were not disclosed until the FDA issued a warning in October 2024.
Implications for Individual Investors:
For individual investors, the lawsuit may result in potential financial compensation if they can prove they suffered losses during the Class Period. If the case is successful, the compensation could include damages, as well as any related securities sold at a loss.
Impact on the Biotech Industry:
The lawsuit against Regeneron is not an isolated incident in the biotech industry. Such lawsuits often raise concerns about transparency and accountability in the industry. If the lawsuit results in a large settlement or judgment, it might deter other companies from withholding critical information from investors. Conversely, it could potentially lead to increased scrutiny and litigation, making it more challenging for biotech companies to operate.
Conclusion:
Regeneron Pharmaceuticals, Inc. investors who purchased the Company’s securities between November 2, 2023, and October 30, 2024, are encouraged to contact The Schall Law Firm before March 10, 2025. If you believe you may be eligible to participate in the class action lawsuit, you should consult with a qualified attorney to discuss your rights and potential remedies.
The lawsuit underscores the importance of transparency and truthful disclosure in the investment world. As investors, it is crucial to stay informed about the companies we invest in and to hold them accountable for any misrepresentations or omissions.
- Regeneron Pharmaceuticals, Inc. is the subject of a class action lawsuit.
- The lawsuit alleges securities law violations during the period from November 2, 2023, to October 30, 2024.
- The Company is accused of downplaying risks associated with its EYLEA® injection.
- Individual investors may be eligible for compensation if they suffered losses during the Class Period.
- The lawsuit’s outcome could impact transparency and accountability in the biotech industry.
